Risks and Benefits of Oral Anticoagulants for Stroke Prophylaxis in Atrial Fibrillation According to Body Mass Index: Nationwide Cohort Study of Primary Care Records in England

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2022 Nov 10

PMID 36353266

Authors

Yoko M Nakao

Kazuhiro Nakao

Jianhua Wu

Ramesh Nadarajah

A John Camm

Chris P Gale

Affiliations

Soon will be listed here.

Abstract

Background: Direct oral anticoagulants (DOACs) are effective and safe alternatives to warfarin for stroke prophylaxis for atrial fibrillation (AF). Whether this extends to patients at the extremes of body mass index (BMI) is unclear.

Methods: Using linked primary and secondary data, Jan 1, 2010 to Nov 30, 2018, we included CHADS-VAS score ≥3 in women and ≥2 in men with AF treated with oral anticoagulants (OACs). Outcomes were ischaemic stroke, major bleeding and all-cause mortality by World Health Organisation BMI classification. Patients who received warfarin were propensity score matched (1:1 ratio) with those who received DOACs and the association of time-varying OAC exposure on outcomes quantified using Cox proportional hazards models.

Findings: We included 29,135 (22,818 warfarin, 6317 DOAC); 585 (2.0%) underweight, 8427 (28.9%) normal weight, 10,705 (36.7%) overweight, 5910 (20.3%) class I obesity and 3508 (12.0%) class II/III obesity. Patients treated with DOACs were older and more comorbid. After 3.7 (SD 2.5) years follow up, there was no difference in risk of ischaemic stroke and major bleeding by BMI category between DOACs and warfarin. Normal weight, overweight and obese class I patients had higher risk of all-cause mortality when treated with DOACs compared with warfarin (HR: 1.45 [95% CI 1.24-1.69], < 0.001; 1.41 [95% CI 1.19-1.66], < 0.001; and 1.90 [95% CI 1.50-2.39], < 0.001), an effect not observed after DOACs became the most common OAC prescription. Amongst underweight patients OAC exposure was associated with greater harm from bleeding than benefit from stroke prevention (benefit to harm ratio, 0.35 [95% CI 0.26-0.44]).

Interpretation: In patients with AF in each BMI classification we found no difference in ischaemic stroke and bleeding risk for DOACs compared with warfarin. Underweight patients experienced divergent risk-benefit patterns from oral anticoagulation compared with other BMI categories.

Funding: None.

Citing Articles

Risk of mortality between warfarin and direct oral anticoagulants: population-based cohort studies.

Wang Z, Matthewman J, Tazare J, Yu Q, Cheung K, Chui C BMC Med. 2024; 22(1):597.

PMID: 39710653 PMC: 11664815. DOI: 10.1186/s12916-024-03808-y.

Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis.

Karakasis P, Ktenopoulos N, Pamporis K, Sagris M, Soulaidopoulos S, Gerogianni M J Clin Med. 2024; 13(13).

PMID: 38999350 PMC: 11242099. DOI: 10.3390/jcm13133784.

Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: A systematic review and meta-analysis.

Adelkhanova A, Oli P, Shrestha D, Shtembari J, Jha V, Shantha G Health Sci Rep. 2024; 7(4):e2044.

PMID: 38650729 PMC: 11033493. DOI: 10.1002/hsr2.2044.

Inequalities in care delivery and outcomes for myocardial infarction, heart failure, atrial fibrillation, and aortic stenosis in the United Kingdom.

Nadarajah R, Farooq M, Raveendra K, Nakao Y, Nakao K, Wilkinson C Lancet Reg Health Eur. 2023; 33:100719.

PMID: 37953996 PMC: 10636273. DOI: 10.1016/j.lanepe.2023.100719.

Prognosis, characteristics, and provision of care for patients with the unspecified heart failure electronic health record phenotype: a population-based linked cohort study of 95262 individuals.

Nakao Y, Nakao K, Nadarajah R, Banerjee A, Fonarow G, Petrie M EClinicalMedicine. 2023; 63:102164.

PMID: 37662516 PMC: 10474358. DOI: 10.1016/j.eclinm.2023.102164.

References

Boriani G, De Caterina R, Manu M, Souza J, Pecen L, Kirchhof P . Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. J Clin Med. 2021; 10(13). PMC: 8269173. DOI: 10.3390/jcm10132879. View

Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J . Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol. 2018; 262:85-91. DOI: 10.1016/j.ijcard.2018.03.060. View

Sterne J, Bodalia P, Bryden P, Davies P, Lopez-Lopez J, Okoli G . Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017; 21(9):1-386. PMC: 5366855. DOI: 10.3310/hta21090. View

Rietman M, van der A D, van Oostrom S, Picavet H, Dolle M, van Steeg H . The Association between BMI and Different Frailty Domains: A U-Shaped Curve?. J Nutr Health Aging. 2018; 22(1):8-15. DOI: 10.1007/s12603-016-0854-3. View

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

Harris D, Thayer D, Wang T, Brooks C, Murley G, Gravenor M . An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS). Eur Heart J Cardiovasc Pharmacother. 2019; 7(1):40-49. PMC: 7811400. DOI: 10.1093/ehjcvp/pvz071. View

Liyanage H, Liaw S, de Lusignan S . Reporting of Studies Conducted using Observational Routinely Collected Data (RECORD) statement: call for contributions from the clinical informatics community. Inform Prim Care. 2013; 20(4):221-4. View

Bhaskaran K, Forbes H, Douglas I, Leon D, Smeeth L . Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD). BMJ Open. 2013; 3(9):e003389. PMC: 3773634. DOI: 10.1136/bmjopen-2013-003389. View

Lee S, Choi E, Park C, Han K, Jung J, Oh S . Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight. J Am Coll Cardiol. 2019; 73(8):919-931. DOI: 10.1016/j.jacc.2018.11.051. View

10.

Chooi Y, Ding C, Magkos F . The epidemiology of obesity. Metabolism. 2018; 92:6-10. DOI: 10.1016/j.metabol.2018.09.005. View

11.

Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J . Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018; 362:k2505. PMC: 6031213. DOI: 10.1136/bmj.k2505. View

12.

Camm A, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S . XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2015; 37(14):1145-53. PMC: 4823634. DOI: 10.1093/eurheartj/ehv466. View

13.

Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X . Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J Clin Med. 2020; 9(6). PMC: 7355744. DOI: 10.3390/jcm9061633. View

14.

Barakat A, Jain S, Masri A, Alkukhun L, Senussi M, Sezer A . Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories. JACC Clin Electrophysiol. 2021; 7(5):649-658. DOI: 10.1016/j.jacep.2021.02.002. View

15.

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler K . 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10):1612-1676. PMC: 11636576. DOI: 10.1093/europace/euab065. View

16.

Herrett E, Gallagher A, Bhaskaran K, Forbes H, Mathur R, van Staa T . Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015; 44(3):827-36. PMC: 4521131. DOI: 10.1093/ije/dyv098. View

17.

Costa O, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore K, Bunz T . Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin. 2020; 36(7):1081-1088. DOI: 10.1080/03007995.2020.1762554. View

18.

Phillips R, Xu J, Peterson L, Arnold R, Diamond J, Schussheim A . Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension. J Am Coll Cardiol. 2018; 71(15):1601-1610. DOI: 10.1016/j.jacc.2018.01.074. View

19.

Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling R . Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2019; 106(2):119-126. PMC: 6993026. DOI: 10.1136/heartjnl-2019-315307. View

20.

Kumar S, de Lusignan S, McGovern A, Correa A, Hriskova M, Gatenby P . Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ. 2018; 360:k342. DOI: 10.1136/bmj.k342. View